Public Employees Retirement Association of Colorado increased its stake in Becton Dickinson and Co (NYSE:BDX) by 146.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 548,844 shares of the medical instruments supplier’s stock after purchasing an additional 326,357 shares during the quarter. Becton Dickinson and comprises about 0.8% of Public Employees Retirement Association of Colorado’s portfolio, making the stock its 26th biggest holding. Public Employees Retirement Association of Colorado owned 0.20% of Becton Dickinson and worth $138,836,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds also recently bought and sold shares of the company. Whittier Trust Co. increased its holdings in Becton Dickinson and by 0.6% in the second quarter. Whittier Trust Co. now owns 6,982 shares of the medical instruments supplier’s stock worth $1,760,000 after buying an additional 40 shares during the last quarter. ProVise Management Group LLC increased its stake in shares of Becton Dickinson and by 2.2% in the second quarter. ProVise Management Group LLC now owns 1,902 shares of the medical instruments supplier’s stock valued at $479,000 after buying an additional 41 shares in the last quarter. Pitcairn Co. increased its stake in shares of Becton Dickinson and by 1.3% in the second quarter. Pitcairn Co. now owns 3,227 shares of the medical instruments supplier’s stock valued at $813,000 after buying an additional 41 shares in the last quarter. Ropes Wealth Advisors LLC increased its stake in shares of Becton Dickinson and by 0.6% in the second quarter. Ropes Wealth Advisors LLC now owns 6,801 shares of the medical instruments supplier’s stock valued at $1,714,000 after buying an additional 43 shares in the last quarter. Finally, Armor Investment Advisors LLC increased its stake in shares of Becton Dickinson and by 0.5% in the second quarter. Armor Investment Advisors LLC now owns 9,265 shares of the medical instruments supplier’s stock valued at $2,335,000 after buying an additional 44 shares in the last quarter. 84.29% of the stock is owned by institutional investors and hedge funds.
A number of brokerages have recently weighed in on BDX. Piper Jaffray Companies lowered their target price on Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. Wells Fargo & Co decreased their price target on Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Wednesday. Morgan Stanley raised their price target on Becton Dickinson and from $250.00 to $261.00 and gave the company an “equal weight” rating in a report on Tuesday, July 16th. Finally, ValuEngine cut Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Five analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $266.09.
Becton Dickinson and stock traded up $0.22 during mid-day trading on Friday, hitting $244.79. The stock had a trading volume of 1,479,428 shares, compared to its average volume of 1,173,922. The stock has a 50-day simple moving average of $251.93 and a two-hundred day simple moving average of $246.89. The stock has a market capitalization of $66.59 billion, a PE ratio of 20.96, a P/E/G ratio of 1.62 and a beta of 1.09. Becton Dickinson and Co has a 12 month low of $208.62 and a 12 month high of $264.74. The company has a current ratio of 1.19, a quick ratio of 0.67 and a debt-to-equity ratio of 0.85.
Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.30 by $0.01. Becton Dickinson and had a return on equity of 15.51% and a net margin of 6.84%. The firm had revenue of $4.58 billion for the quarter, compared to analysts’ expectations of $4.57 billion. During the same quarter last year, the business earned $2.93 earnings per share. The company’s revenue was up 4.1% compared to the same quarter last year. Sell-side analysts expect that Becton Dickinson and Co will post 12.58 earnings per share for the current fiscal year.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Basic Economics
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.